Drugs / Xinlikang capsules
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT07084662 | Sep 2025 → Aug 2028 expected | diffuse large B-cell lymphoma | Sun Yat-sen University | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Xinlikang capsules | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07084662 ↗ |